Clinical trial · Interventional
A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
A Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Efficacy of BR790 Monotherapy in Subjects With Advanced Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase II clinical trial dose (RP2D) .The study is divided into two phases: dose escalation phase and dose expansion phase.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BR790 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 5-65mg QD
- interventionNames
- Drug: BR790
Primary outcomes (3)
- measure
- Dose limiting toxicity (DLT)
- timeFrame
- up to 32 day
- measure
- maximum tolerated dose (MTD)
- timeFrame
- up to 32 day
- measure
- recommended phase II clinical study dose (RP2D)
- timeFrame
- up to 32 day
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Sign informed consent voluntarily. * Age ≥18 and ≤75 years old. * Subjects with advanced solid tumors diagnosed by histology or cytology，whose desease progressed after standard treatment or have no standard treatment. * Had at least one measurable lesion. * ECOG≤1. * Expected survival period ≥ 3 months. Exclusion Criteria: * Any previous treatment with SHP-2 inhibitor. * Symptomatic brain metastases. * Subjects with thoracic/ascites fluid that need drainage or intervention. * Subjects with not enough organ functional reserve at baseline, which met at least one of the following criteria： ANC\<1.5×10\^9/L PLT\<100×10\^9/L Hb\<90g/L TBIL\>1.5×ULN ALT, AST\>2.5×ULN (without liver metastases) or ALT, AST\>5×ULN (with liver metastases), Cr \>1.5×ULN. * With uncontrolled severe disease.
References
Publications (0)
Data not yet available